Is Pathologic Complete Response a Valid Surrogate Parameter of Treatment Efficacy in HER2 Positive Breast Cancer Patients Undergoing Primary Chemotherapy Plus Trastuzamab?
- Resource Type
- Academic Journal
- Source
- Journal of Clinical Oncology. Nov 01, 2005 23(31):8130-8131
- Subject
- Language
- English
- ISSN
- 0732-183X